GRI Bio, Inc. (GRI) Upgraded to Buy: What Does It Mean for the Stock?
GRI Bio Inc GRI
$2.05
▼ -1.91%
($-0.04)
⬇️ Below Yest. Low
🎈 Low Float
Open
$2.07
Prev Close
$2.09
Day Range
$1.95 – $2.08
52W Range
$1.36 – $64.12
Market Cap
$4.48M
Beta
-1.13
EPS (TTM)
$-51.65
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-02-10 |
| Shares Out. | 1,770,000 |
| Website | gribio.com/ ↗ |
| Phone | 16194001171 |
| Employees | 5 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$1.6M |
| Free Cash Flow | -$10.4M |
| Total Assets | $11.4M |
| Total Liabilities | $1.1M |
| Equity | $10.3M |
About GRI Bio Inc
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
GRI Bio Inc is a publicly traded company under the ticker symbol GRI on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
6 analysts (2026-09-01)